Aberdeen Group plc Grows Stock Holdings in Denali Therapeutics Inc. $DNLI

Key Points

• Aberdeen Group plc significantly increased its holdings in Denali Therapeutics by 88.9% during the first quarter, owning approximately 0.52% of the company with shares valued at $10.33 million.
• Insider trading activity revealed that Alexander O. Schuth and Carole Ho each sold 2,937 shares at an average price of $13.58, resulting in a decrease of their ownership positions by 1.20% and 1.33%, respectively.
• Denali Therapeutics reported an EPS of ($0.72) for the latest quarter, beating analysts' estimates, while the stock has a consensus rating of Buy and a price target of approximately $33.62.

Aberdeen Group plc raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 88.9% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 759,815 shares of the company's stock after purchasing an additional 357,533 shares during the quarter. Aberdeen Group plc owned 0.52% of Denali Therapeutics worth $10,330,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of DNLI. Caitong International Asset Management Co. Ltd raised its holdings in shares of Denali Therapeutics by 277.0% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company's stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth about $62,000. Point72 Hong Kong Ltd purchased a new stake in Denali Therapeutics during the 4th quarter valued at approximately $65,000. Finally, GAMMA Investing LLC increased its holdings in Denali Therapeutics by 253.8% in the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company's stock valued at $108,000 after acquiring an additional 5,705 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Analyst Upgrades and Downgrades

DNLI has been the topic of a number of research reports. HC Wainwright reduced their price objective on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. TD Cowen raised shares of Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Robert W. Baird lowered their target price on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Bank of America dropped their price objective on Denali Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, Morgan Stanley cut their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, August 18th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of "Buy" and an average target price of $33.62.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock traded up $0.08 during trading on Monday, hitting $15.57. 1,386,024 shares of the company's stock were exchanged, compared to its average volume of 1,818,628. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -5.56 and a beta of 1.36. The business has a 50-day simple moving average of $14.32 and a 200-day simple moving average of $14.93. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period in the previous year, the business posted ($0.59) earnings per share. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 242,346 shares in the company, valued at $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 2,937 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the transaction, the insider owned 217,391 shares of the company's stock, valued at $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 501,962 shares of company stock valued at $7,520,799. Company insiders own 12.50% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.